Just reported
From Merck's results release of 29 de outubro de 2026; its quarterly report has since been filed.
Actual
US$ 18,09B
+4,7% y/y
+8,9% q/q
Guided
—
No guide given
Actual
US$ 2,04
-12% y/y
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →As participações na receita são estimativas para FY2025, não números de um relatório oficial.
Keytruda and Keytruda Qlex
Cancer medicines. Keytruda is given into a vein; Keytruda Qlex is a form given as an injection under the skin.
Gardasil and Gardasil 9
Vaccines that help prevent certain cancers and other diseases caused by some types of human papillomavirus.
Januvia and Janumet
Prescription medicines used to help lower blood sugar in adults with type 2 diabetes.
Winrevair
A medicine for adults with pulmonary arterial hypertension, a disease that raises blood pressure in the arteries from the heart to the lungs.
Lipfendra
An oral medicine used with diet and exercise to lower low-density lipoprotein cholesterol in adults with high cholesterol.
Bravecto
A range of medicines that protect dogs and cats against fleas and ticks, including oral, topical and injectable forms.
Demonstrações financeiras completas →
Merck discovers, develops, manufactures and sells prescription medicines and vaccines for people, including cancer treatments such as Keytruda and vaccines such as Gardasil. Its Animal Health business sells medicines, vaccines and animal identification and monitoring products to veterinarians, farmers and other animal-care businesses.
Construído a partir dos próprios documentos de Merck & Co., Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
The themes Merck is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
US$ 147,76+0,6%fechamento 13 de nov.
Números até 30 de setembro de 2026, do 10-Q arquivado em 4 de novembro de 2026
Merck makes prescription medicines and vaccines for people, and medicines, vaccines and monitoring products for animals.
Grade A
A faixa sob o preço mostra a nota em cada data, calculada só com os documentos já públicos naquele momento.
Mostrando 2 de 41 trimestres do histórico de notas de Merck & Co., Inc.. Os outros 39 vão até novembro de 2016.